Ms June Alice Brose, DDS | |
Unit 26610, Wuerzburg Dental Activity Credentials Office, Apo Ae, NC 09244 | |
(931) 804-3933 | |
Not Available |
Full Name | Ms June Alice Brose |
---|---|
Gender | Female |
Speciality | Dentist - Pediatric Dentistry |
Location | Unit 26610, Apo Ae, North Carolina |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1063460046 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1223P0221X | Dentist - Pediatric Dentistry | KY4316 (Kentucky) | Primary |
Mailing Address | Practice Location Address |
---|---|
Ms June Alice Brose, DDS Unit 26610, Wuerzburg Dental Activity Credentials Office, Apo Ae, NC 09244 Ph: (931) 804-3933 | Ms June Alice Brose, DDS Unit 26610, Wuerzburg Dental Activity Credentials Office, Apo Ae, NC 09244 Ph: (931) 804-3933 |
News Archive
A clinical trial designed to replace the genetic defect causing the most common form of muscular dystrophy has uncovered an unexpected aspect of the disease. The trial, based on therapy designed by scientists at the University of North Carolina at Chapel Hill School of Medicine, showed that some patients mount an immune response to the dystrophin protein even before they have received the gene therapy.
Controlling pain during childbirth and post delivery may reduce the risk of postpartum depression, writes Katherine Wisner, M.D., a Northwestern Medicine- perinatal psychiatrist, in a July 23 editorial in Anesthesia & Analgesia.
A promising cancer drug, first discovered in a mushroom commonly used in Chinese medicine, could be made more effective thanks to researchers who have discovered how the drug works. The research is funded by the Biotechnology and Biological Sciences Research Council and was carried out at The University of Nottingham.
Prism Pharmaceuticals, Inc. announced today that the U.S. Food & Drug Administration has approved the supplemental new drug application for NEXTERONE (amiodarone HCl) Premixed Injection, the first and only premixed intravenous (IV) bag formulation of the antiarrhythmic agent amiodarone IV.
› Verified 4 days ago